Physician profile
Robert A Johnson
NPI 1245262336
$2,378.82
in general payments reported to CMS, 2019-2025
40 companies · $551 in 2025
The $551 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $326 · 2020: $195 · 2021: $282 · 2022: $254 · 2023: $275 · 2024: $496 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,321.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $251.50 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $199.04 | 2019-2025 | Ninlaro |
| E.R. Squibb & Sons, L.L.C. | $154.42 | 2019-2025 | Opdualag, Opdivo |
| Abbvie INC. | $147.40 | 2020-2025 | |
| Celgene Corporation | $139.77 | 2023-2025 | Reblozyl |
| Exelixis INC. | $120.49 | 2019-2024 | Cabometyx |
| Eisai INC. | $115.90 | 2021-2025 | |
| Glaxosmithkline, LLC. | $108.42 | 2022-2025 | Ojjaara, Zejula, Jemperli |
| Astrazeneca Pharmaceuticals LP | $100.63 | 2020-2025 | Enhertu |
| Incyte Corporation | $97.95 | 2019-2024 | Jakafi, Pemazyre |
| Seagen INC. | $95.33 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $66.65 | 2019-2022 | |
| Genzyme Corporation | $64.04 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $61.13 | 2024-2025 | Libtayo |
| Genentech USA, INC. | $60.03 | 2019-2023 | Lunsumio |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Pharmaceuticals LLC | $56.16 | 2021-2024 | |
| Amgen INC. | $45.46 | 2019-2020 | |
| Agios Pharmaceuticals, INC. | $41.99 | 2019-2022 | |
| Beigene USA, INC. | $39.37 | 2020-2024 | Brukinsa |
| Lilly USA, LLC | $38.75 | 2019-2020 | |
| Rigel Pharmaceuticals, INC. | $29.56 | 2023 | Rezlidhia, Tavalisse |
| Astellas Pharma US INC | $28.72 | 2025 | Vyloy |
| G1 Therapeutics, INC. | $28.33 | 2022 | |
| Tempus Ai, INC | $27.62 | 2024 | Xt Cdx |
| Taiho Oncology, INC. | $27.15 | 2020-2025 | |
| Genmab U.S., INC. | $24.34 | 2024 | Epkinly |
| Tersera Therapeutics LLC | $24.14 | 2025 | Zoladex |
| Alexion Pharmaceuticals, INC. | $20.70 | 2025 | Ultomiris |
| Dova Pharmaceuticals | $20.60 | 2021 | |
| Array Biopharma INC | $17.65 | 2025 | Braftovi |
| Livanova USA, INC. | $14.67 | 2019 | |
| Aveo Pharmaceuticals, INC. | $14.05 | 2021 | |
| Adc Therapeutics America, INC. | $13.84 | 2024 | |
| Daiichi Sankyo INC. | $12.29 | 2021 | |
| Janssen Biotech, INC. | $12.18 | 2020 | |
| Acceleron Pharma, INC. | $12.01 | 2020 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Kyowa Kirin, INC. | $11.88 | 2021 | |
| Emmaus Medical, INC. | $11.40 | 2023 | Endari |
| Tesaro, INC. | $11.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.